Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer

Jun Shiihara | Fumiyoshi Ohyanagi | Hikari Amari | Minemichi Toda | Hiroki Tahara | Motoi Yuzawa | Yuki Maeda | Motoko Nomura | Yoshiko Mizushina | Yoshiaki Nagai | Hiromitsu Ohta | Yasuhiro Yamaguchi

1Division of Respiratory Medicine, Clinical Department of Internal Medicine, Jichi Medical University Saitama Medical Center, Saitama, Japan
2Division of Respiratory Medicine, Saitama Cancer Center, Saitama, Japan
3Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan

Correspondence
Yasuhiro Yamaguchi, Division of Respiratory Medicine, Clinical Department of Internal Medicine, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama-city, Saitama 330-8503, Japan.
Email: yamayasu@jichi.ac.jp

Abstract
Lung cancers with anaplastic lymphoma kinase (ALK) rearrangements are highly sensitive to treatment with ALK tyrosine kinase inhibitors (TKIs). Due to the very low rate of patients with squamous cell carcinoma enrolled in clinical trials, the efficacy of ALK inhibitors in patients with ALK-rearranged squamous cell carcinoma in the lung remains unclear. Herein, we present the case of a 70-year-old female patient with squamous cell lung cancer harboring the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene. The patient was treated with the ALK-TKI alectinib as first-line regimen and achieved a dramatic response without severe adverse events, demonstrating alectinib as a therapeutic option for patients with ALK-positive squamous cell carcinoma.

KEYWORDS
alectinib, anaplastic lymphoma kinase, lung cancer, squamous cell cancer

INTRODUCTION
Specific molecular changes in certain lung cancers provide excellent opportunities for molecular targeted therapies. Echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement is found in 2%–7% of patients with non-small cell lung cancer (NSCLC), a leading cause of cancer-related deaths worldwide. However, ALK mutations are reported in only 0%–2.5% of patients with squamous cell cancer (SCC) of the lung.

The ALK tyrosine kinase inhibitor (TKI) alectinib exhibits impressive single-agent activity in ALK-positive lung adenocarcinomas with an objective response rate (RR) of 70% and a median progression-free survival of nearly 26 months. Due to the low percentage of patients with SCC enrolled in clinical trials, the efficacy of ALK TKIs in these patients is unclear. Herein, we present a patient with SCC harboring EML4-ALK rearrangement successfully treated with alectinib.
and strongly positive (3+) for ALK by intercalated antibody-enhanced immunohistochemistry with an ALK detection kit (Nichirei Bioscience; Figure 2(d)). Based on fluorescence in situ hybridization (FISH) using break-apart probes for ALK (Figure 2(e)), the patient was diagnosed with SCC harboring EML4-ALK rearrangement and treated with alectinib (300 mg twice daily). Two months later, PET-CT images revealed dramatic shrinkage in the size of primary tumor in the left upper lung lobe and reduction in the size of multiple muscular, bone, and skin metastases (Figure 1(b)); therefore, the patient was considered to have achieved partial response to alectinib according to the Response Evaluation Criteria in Solid Tumors guidelines (version 1.1). Although she experienced recurrence after a durable response of 9.5 months, there were no severe alectinib-related adverse events.

DISCUSSION

Lung SCC is the second most common histological NSCLC type, accounting for 20%–30% of all cases. In the last decade, advances in the identification of therapeutically
relevant genetic alterations in EGFR and ALK[^4] have revealed that these events occur almost exclusively in adenocarcinoma, but not in SCC.^[3] Several recent case studies report ALK rearrangement in SCC[^7-9] based on conventional pathological diagnosis using small samples obtained by bronchoscopy or needle biopsy. According to the American Society of Clinical Oncology guidelines[^10], molecular testing is recommended in fully resected lung cancer specimens because small biopsy specimens do not represent the precise characteristics of the entire tumor. The patient in this report was diagnosed based on the evaluation of fully resected tumor, with histological subtype confirmation by immunohistochemistry and ALK detection using immunohistochemistry and FISH. The patient in this report was a novel case of pure SCC without an adenocarcinoma component, with accompanying data on efficacy and duration of response to alectinib.

In Japan, the second-generation ALK-TKI alectinib was approved in July 2014 for patients with ALK-rearranged NSCLC, based on the results of the AF-001JP study.^[11] Furthermore, the results from two phase III trials, JALEX and ALEX, showed superior efficacy and lower toxicity of alectinib versus crizotinib for first-line treatment of ALK-positive NSCLC[^4-12]; the median progression-free survival (PFS) and overall RR with alectinib were 25.7–34.1 months and 70%–80%, respectively, in these trials.

In the patient in this report, the CT scan three weeks after the initiation of alectinib revealed tumor shrinkage and the duration of response was 9.5 months. Compared with the previous ALK-rearranged SCC case reports, the PFS of this case is longer than that of the four case reports treated with crizotinib (9, 7.1, 3, and 6 months, respectively)^[7,13-15^] and that of the nonresponse case treated with alectinib.^[8] It is also similar to that of the response case treated with alectinib (>11 months and > 9 months, respectively).[^9,16^] Our case and these case reports suggest that alectinib has a longer PFS, even in ALK-rearranged SCC than crizotinib.

Previous studies have suggested that squamous cell carcinoma shows a poor response to TKIs than adenocarcinoma.[^17] A pooled analysis of EGFR-TKI to EGFR-mutated SCC revealed that the RR and median PFS were 30% and 3.1 months, respectively. These results are clearly inferior to the data for EGFR-mutated adenocarcinoma, including the reported RR and median PFS of 70%–80% and 9–11 months, respectively.[^6] On the other hand, there is no large-scale study that shows the efficacy of ALK-TKI to ALK-rearranged SCC because of the small number of patients. The PFS of this case was 9.5 months, which is shorter than the previously reported PFS of adenocarcinoma, but some SCC cases show promising PFS.[^9,16] Further accumulation of clinical experience is needed to clarify the effectiveness of ALK-TKI for ALK-rearranged SCC. For the benefit of patients, genetic testing is important, even if the type of pathology is SCC.

The present case report has several limitations. The resected specimen for histological analysis was obtained from a subcutaneous tumor in the left thigh, and it remains possible that an adenocarcinoma component might have been present in other lesions, or that there may be histological discrepancies between the primary and metastatic lesions due to the heterogeneity and distribution of the tumor.

In conclusion, molecular testing for driver mutations should be considered in young patients with minimal or no smoking history, even if the histological findings correspond with those of SCC. Alectinib represents a reasonable treatment option in ALK-rearranged lung SCC.

**CONFLICT OF INTEREST**
None declared.

**REFERENCES**

1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–59.

2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

3. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012;18:2443–51.

4. Hida T, Nokiara H, Kondo M, Kim KY, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390:29–39.

5. Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669–92.

6. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.

7. Wang W, Song Z, Zhang Y. Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma translocation: A case report. Thorac Cancer. 2016;7:355–7.

8. Tamiya A, Shimizu S, Atagi S. A case of squamous cell carcinoma harboring an EML4-ALK rearrangement that was unsuccessfully treated with the ALK inhibitor alectinib. J Thorac Oncol. 2015;10:e74–e75.

9. Mamesaya N, Nakashima K, Naito T, Nakajima T, Endo M, Takahashi T. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature. BMC Cancer. 2017;17:471.

10. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leigl NB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice guideline update. J Clin Oncol. 2018;36:911–9.

11. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol. 2013;14:590–8.

12. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–38.

13. Vergne F, Quere G, Andrieu-Key S, Descourt R, Quintin-Roué I, Talagas M, et al. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer? Lung Cancer. 2016;91:67–9.

14. Mikes RE, Jordan F, Hutarew G, Studdnicka M. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer. Lung Cancer. 2015;90:614–6.
15. Zhang Q, Wang J, Zhang S. ALK-rearranged squamous cell lung cancer: a case report. Int J Clin Exp Pathol. 2015;8:2195–8.

16. Sagawa R, Ohba T, Ito E, Isogai S. ALK-positive squamous cell carcinoma dramatically responded to alectinib. Case Rep Oncol Med. 2018;12:235–8.

17. Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci. 2011;102:1032–7.

How to cite this article: Shiihara J, Ohyanagi F, Amari H, Toda M, Tahara H, Yuzawa M, et al. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer. Thorac Cancer. 2021;12:2420–3. https://doi.org/10.1111/1759-7714.14092